HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Metastatic Uveal Melanoma is a rare and aggressive form of cancer that originates in the eye's uvea, the middle layer of the eye containing the choroid, ciliary body, and iris. Unlike more common skin melanomas, uveal melanoma develops in the eye and can spread to other parts of the body. Typically, uveal melanoma doesn't present early symptoms, making early detection challenging. As the disease progresses, patients may experience blurred vision, changes in the appearance of the eye, and in advanced stages, pain. Once uveal melanoma metastasizes, spreading beyond the eye, it often targets the liver. Liver metastases significantly worsen the prognosis, as treatment options become limited. Traditional treatments, such as surgery, radiation, and chemotherapy, may be employed to manage localized disease, but the effectiveness diminishes in the metastatic stage. The prognosis for metastatic uveal melanoma is generally poor, with a limited survival rate. Research into targeted therapies and immunotherapies is ongoing to improve outcomes for patients with this challenging condition. Early detection, though difficult, remains crucial for better treatment prospects, highlighting the importance of regular eye examinations, especially for individuals at risk. In summary, metastatic uveal melanoma poses a serious threat to those affected, with limited treatment options and a challenging prognosis. Ongoing research and advancements in medical science are essential in improving our understanding and developing more effective treatments for this rare and aggressive form of cancer.
